pharmaphorum

MARCH 8, 2022

After a few years, I decided I wanted to move into the commercial side of the business, so I completed an MBA and went on to hold various positions in Corporate Business Development, Life Science and Healthcare. I have been general manager for Merck Healthcare UK & Ireland since 2020.

Life Science 98

Life Science Engineer Scientist Doctor 98

pharmaphorum

OCTOBER 12, 2022

David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says.

Genome 105

Genome Genomics Medicine Development 105

The Pharma Data

JANUARY 4, 2021

Longwood has a robust research department with 7 post doctorates conducting research in molecular biology, microbiology, genomics, cancer biology, and immunology and publishing over 75 publications in different scientific journals in the past 5 years. Barber also serves on Kiromic’s Scientific Advisory Board. About Longwood University.

In-Vivo 40

In-Vivo Development Immune Response Big Data 40

The Pharma Data

NOVEMBER 15, 2020

Prior to Celgene, she held leadership roles in marketing, sales and new business development from 2002 to 2011 at Johnson & Johnson. Most recently, she was a senior executive at Celgene Corporation, where she led corporate strategy from 2012 to 2017. Before that, Ms.

Clinical Trials 40

Clinical Trials Clinical Trials Production Trials 40

Pharmaceutical Technology

MARCH 20, 2023

One significant growth area is the rise of genomics. Genomics is set to have a major impact on understanding, preventing, and treating a huge range of diseases; cell and gene therapies will bolster oncology investment, for example, with several such drugs currently in development.

Gene Therapy 225

Gene Therapy Genome Genomics Gene 225

Pharmaceutical Technology

DECEMBER 22, 2022

The funding will offer capital to extend Blueprint’s varied pipeline toward marketing as well as to continue seeking strategic and synergistic business development prospects. Deerfield and Illumina win the Research and Development award this year due to their commitment to research into AI-driven therapies. Innovation.

Insulin 130

Insulin Production Development Genetics 130

pharmaphorum

OCTOBER 1, 2021

It has made Oxford Nanopore’s chief executive and cofounder Gordon Sanghera an on-paper fortune of £63 million, while another cofounder – chief business development officer Spike Willcocks – is now worth £30 million. Chief technology officer Clive Brown is also sitting on a £10 million stake.

Marketing 52

Marketing Genome Genomics Business Development 52

The Pharma Data

JANUARY 12, 2021

Marianne De Backer, Head of Business Development & Licensing in Bayer’s Pharmaceuticals Division, pictured above. As a result, the company settled on four areas of focus – iPSC, allogenic CAR-T, genome mutations and gene editing. Photo courtesy of Bayer.

Gene Therapy 52

Gene Therapy Gene Gene Editing Business Development 52

The Pharma Data

AUGUST 6, 2020

FDA for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This approval was based on the Phase 3 CheckMate -9LA study. In May, the company announced the U.S.

Production 52

Production Branding Marketing Containment 52

The Pharma Data

JUNE 7, 2023

. “Complementing in-house expertise with external collaboration continues to be a priority in areas of high unmet medical need where insufficient, or no treatment options are currently available,” said Friedemann Janus, acting Head of Business Development and Licensing/Open Innovation, Pharmaceuticals Division, Bayer.

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

The Pharma Data

OCTOBER 26, 2020

50%) with no EGFR or ALK genomic tumor aberrations. L1 expression with no EGFR or ALK genomic tumor aberrations at the IASLC 2020 North America Conference on Lung Cancer (NACLC). The FDA has granted V181, the company’s investigational dengue vaccine in Phase 1 development, Fast Track designation.

Sales 40

Sales Vaccine Vaccination Production 40